BioSpace News Archive

Ascentage Pharma (6855.HK) announced today that it has released the latest clinical data of its dual Bcl-2/Bcl-xL inhibitor, APG-1252 (pelcitoclax), combined with osimertinib for the treatment of patients with EGFR-mutant non-small cell lung cancer (NSCLC) in a Mini Oral at the 2023 European Society of Medical Oncology (ESMO) Congress.

VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”), a multi-national epigenetics company, has unveiled what it believes to be an entirely new cancer detection method at ESMO 2023¹, the annual congress of the European Society for Medical Oncology.

Alzamend Neuro, Inc. today announced that it has submitted an investigational new drug (“IND”) application to the U.S. Food and Drug Administration (“FDA”) for the initiation of study AL001-MDD01, a Phase IIA plasma/brain pharmacokinetics clinical study of AL001 for adjunctive treatment of patients with MDD.

Persephone Biosciences Inc. today announced that it has appointed Daniel Bradbury as Chair of the Board of Directors.

venacy, a specialty pharmaceutical company focused on developing, manufacturing, and delivering critical medications, announced its launch.

Adlai Nortye Ltd. and Nucleai is pleased to announce the receipt of the ESMO 2023 Best Poster Award for the Sunday, October 22, 2023 poster session with the presentation of the study “Utilizing H&E Images and Digital Pathology to Predict Response to Buparlisib in SCCHN”.

BerGenBio ASA announced that the full results of its Phase 2 BGBC008 study of bemcentinib and pembrolizumab in second line Non-Small Cell Lung Cancer were presented during the European Society of Clinical Oncologists Annual Meeting 2023.

Hummingbird Bioscience announced presentation of positive clinical data for the dose escalation part of the HMBD-001 Phase I/IIa trial at the European Society for Medical Oncology Congress 2023.

Ryvu Therapeutics announced updated clinical Phase I data from RVU120 Phase I/II study in patients with relapsed/refractory metastatic or advanced solid tumors, presented at the European Society for Medical Oncology Congress 2023, taking place October 20-24 in Madrid, Spain.

Genexine together with PT Kalbe Genexine Biologics, a joint venture clinical-stage biotechnology company between Genexine and PT Kalbe Farma that focused on bringing biologics medical innovation to international markets, announced the approval of its long-acting erythropoietin, Efepoetin alfa, by the Indonesian Ministry of Food and Drug Safety for the treatment of chronic kidney disease induced anemia in non-dialysis patients.